ArticleJapanese journal of ophthalmology
Persistent epithelial defects due to neurotrophic keratopathy treated with a substance p-derived peptide and insulin-like growth factor 1.
Article in Japanese journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Pooled it
- Differential contributions of impaired corneal sensitivity and reduced tear secretion to corneal epithelial disorders.Japanese journal of ophthalmology · 2012Trial
- Efficacy of substance P and insulin-like growth factor-1 peptides for preventing postsurgical superficial punctate keratopathy in diabetic patients.Japanese journal of ophthalmology · 2009Trial
- Corneal nerve regeneration: treatments and monitoring approaches.Annals of medicine · 2026Review
- Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS).Eye (London, England) · 2026Article
- Endogenous Therapeutic Agents for Acute Corneal and Ocular Surface Injuries.Translational vision science & technology · 2026Review
- Review
- Review
- Enhanced adipose-derived stem cells with IGF-1-modified mRNA promote wound healing following corneal injury.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Neurotrophic keratopathy: current challenges and future prospects.Annals of medicine · 2022Review
- Modulating the tachykinin: Role of substance P and neurokinin receptor expression in ocular surface disorders.The ocular surface · 2022Review
- Review
- New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis.Frontiers in pharmacology · 2022Review
- Equine Umbilical Cord Serum Composition and Its Healing Effects in Equine Corneal Ulceration.Frontiers in veterinary science · 2022Article
- Corneal neuromediator profiles following laser refractive surgery.Neural regeneration research · 2021Review
- Role of the Neurokinin-1 Receptor in the Promotion of Corneal Epithelial Wound Healing by the Peptides FGLM-NH2 and SSSR in Neurotrophic Keratopathy.Investigative ophthalmology & visual science · 2020Article
- The IGF/Insulin-IGFBP Axis in Corneal Development, Wound Healing, and Disease.Frontiers in endocrinology · 2020Review
- Persistent Corneal Epithelial Defects: A Review Article.Medical hypothesis, discovery & innovation ophthalmology journal · 2019Review
- Neprilysin inhibition promotes corneal wound healing.Scientific reports · 2018Article
- Neurotrophic Keratopathy after Trigeminal Nerve Block for Treatment of Postherpetic Neuralgia.Case reports in ophthalmological medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe loss of corneal sensation results in the development of persistent corneal epithelial defects. The combination of a substance P-derived peptide, phenylalanine -glycine-leucine-methionine (FGLM)-amide, and insulin-like growth factor 1 (IGF-1) stimulates corneal epithelial migration in vitro and corneal epithelial wound closure in vivo. The clinical efficacy of eye drops containing FGLM-amide and IGF-1 for the treatment of persistent epithelial defects in individuals with neurotrophic keratopathy was examined in a prospective open study.
methodsEleven patients with persistent corneal epithelial defects associated with neurotrophic keratopathy were treated for up to 28 days by the administration of eye drops containing FGLM-amide and IGF-1. The course of epithelial healing was monitored by slit-lamp examination, and visual acuity was measured before and after treatment.
resultsComplete epithelial resurfacing was achieved in eight of the nine (89%) cases of persistent epithelial defects in the nine patients who received the full course of treatment. Epithelial defects had completely resurfaced in two of nine (22%) and five of nine (56%) cases within 1 and 2 weeks, respectively, after treatment initiation. No adverse effects of treatment were observed in any of the 11 patients.
conclusionsEye drops containing FGLM-amide and IGF-1 induced the rapid resurfacing of persistent epithelial defects in individuals with neurotrophic keratopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.